Main > ONCOLOGY (**) > Skin Cancer>Melanoma>MET *** > Treatment > USA. B. LAG-3 MAb+PD-1 MAb IV>

---

USA. B. LAG-3 MAb+PD-1 MAb IV>'s subsections
(*) USA Approval Date: 2022. 03.18
>Infusion
Company
Generic Names>
LAG-3: Lymphocyte Activation Gene-3
or UnResectable
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 7
Patent>UpDate: 2022. 03.22
PR Web-Site
TM:

USA. B. LAG-3 MAb+PD-1 MAb IV>'s products
This section has no products